Roivant Sciences (ROIV) Operating Expenses (2020 - 2025)

Roivant Sciences has reported Operating Expenses for 6 years, with the latest figure at $341.2 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 20.38% year-over-year to $341.2 million; the trailing twelve-month figure through Mar 2026 stood at $936.0 million (up 10.1% YoY), and the FY2026 full-year result was $1.3 billion, up 13.2% from the prior year.
• Operating Expenses for Q4 2025 stood at $341.2 million, up from $307.8 million in the prior quarter.
• The five-year high for Operating Expenses was $698.4 million in Q3 2021, with the low at $162.1 million in Q2 2021.
• Historically, Operating Expenses has averaged $309.6 million across 5 years, with a median of $287.1 million in 2025.
• Annual changes were most pronounced in 2021 — Operating Expenses jumped 342.42% — and 2022, when it slumped 58.01%.
• Roivant Sciences' Operating Expenses stood at $270.4 million in 2021, then surged by 46.15% to $395.1 million in 2022, then plunged by 40.14% to $236.5 million in 2023, then gained by 19.82% to $283.4 million in 2024, then climbed by 20.38% to $341.2 million in 2025.
• The last three Operating Expenses figures came in at $341.2 million (Q4 2025), $307.8 million (Q3 2025), and $287.1 million (Q2 2025), per Business Quant data.